Source: Washington Examiner Author: Michael Lee

A Yale University doctor took aim at Dr. Anthony Fauci for the infectious disease expert’s dismissal of hydroxychloroquine as a potential treatment for COVID-19.

“I really wish Dr. Fauci would say something in terms of evidence. He never quotes any studies. It’s hard to know if he has any evidence,” Dr. Harvey Risch said of Fauci’s dismissal of the drug during an appearance on the Ingraham Angle. “The study we published is a review of all of the evidence for early treatment as a whole.”

Risch continued by pointing out that there are many treatments that work well in addition to hydroxychloroquine.

“It’s not just one drug,” Risch said. “It’s not just hydroxychloroquine. There are many drugs that can be used, as we have seen this week. … There is a whole new repertoire … of drugs that work in early treatment. And we combine them to get maximal benefits. That’s how we treat early COVID, and it works well.”

“It’s astonishing,” Risch continued. “Everything has become politicized, and it’s like Big Brother is watching over every … move with a script behind the scenes that nobody understands. These drugs are inexpensive. They are generic. Nobody is making a huge profit over them, and maybe that’s the bottom line.”

Risch also took aim at some of the contradicting statements from President Biden’s COVID response team and Fauci, saying that there are a lot of “gray zones” that nobody knows the true answer to.

“There are a lot of gray zones and lack of specific knowledge,” Risch said. “Nobody quite knows the answer. … The new viral strains — the vaccine and natural immunity seem to have some degree of immunity against them but not as much as the normal strain. Whether that will be enough or not, and we need backups for the vaccine is something we will know empirically when it gets here.”

Fauci did not immediately respond to the Washington Examiner’s request for comment.

Risch’s comments come as new research has begun to emerge, showing that hydroxychloroquine may be an effective treatment for some COVID-19 symptoms after all.

“We make it clear we can’t recommend it to be given,” said Andrew Ip, a lymphoma physician and director of the Division of Outcomes and Value Research at the John Theurer Cancer Center, said of a study he helped author. “This is only an observational study. We can only recommend it in the context of a clinical trial. There may be a benefit for using this drug in an outpatient setting.”

That study came on the heels of another in November, which found that “the odds of hospitalisation of treated patients was 84% less than in the untreated patients.”

Hydroxychloroquine became the center of controversy when then-President Donald Trump mentioned its effectiveness during a press conference, causing many members of the medical community and media to dispute Trump’s optimism. Major tech companies also moved to censor information that contained positive news about the drug’s results.









Related: HCQ Peer-reviewed: Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Peer-Reviewed Journal Reports Hydroxychloroquine Can Reduce Mortality Rates In COVID-19 Patients

HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

COVID-19: A realistic approach to community management – HCQ & IVM in concert with vaccination

The FLCCC Alliance— On a mission to Save Thousands & Slow the Pandemic

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »